News

Basel, March, 23, 2021 — Novartis has reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of ¹⁷⁷Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone.

March 18, 2021 - Imaging Endpoints is making an impact on a global scale – and we are nearing an announcement of new offices in both Switzerland and China. Our primary offices are in Scottsdale, AZ, and Walltham, MA, USA;…   Read More

March 16, 2021 - Jatinder Kaur, Executive VP of Imaging Operations, says the role of Artificial Intelligence (AI) in Healthcare is very exciting. To that end, "IE is continually working in automating and integrating different datasets and systems, leveraging our…   Read More

March 11, 2021 - Today is recognized as World Kidney Day, aimed at raising global awareness of the kidney's importance and some of the ailments that affect it. Kidney cancer has a devastating impact on patients and their families, and…   Read More

Imaging Endpoints is likely the fastest-growing global iCRO – and that facilitates an exceptional opportunity for professional growth. We seek the best talent for dynamic positions, both work-from-home and in-office positions, in 7 countries: USA, Netherlands, Switzerland, France, Germany, India…   Read More